SEC Form 10-Q filed by Amarin Corporation plc
$AMRN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Underweight | JP Morgan | |
| 10/25/2023 | $3.00 → $1.00 | Buy → Hold | Jefferies |
| 1/6/2023 | $1.30 → $3.00 | Hold → Buy | Jefferies |
| 5/6/2022 | Neutral → Underweight | JP Morgan | |
| 5/5/2022 | $10.00 → $3.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/5/2022 | $10.00 → $3.00 | Buy → Neutral | H.C. Wainwright |
| 5/4/2022 | Outperform → Market Perform | Northland Capital | |
| 2/16/2022 | $11.00 → $10.00 | Outperform | SVB Leerink |
JP Morgan resumed coverage of Amarin with a rating of Underweight
Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously
Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously
3 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024. As part of the Annual General Meeting, shareholders
-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15. Mr. Provoost, who most recently served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma, Inc., brings more than 20 years of corporate legal experience, having served most of his career in large and medium-sized pharmaceutical companies. "We are excited to welcome Jonathan to Amarin, where he will
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association's Scientific Sessions, November 16-18, 2024 in Chicago, IL. "The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA®/VAZKEPA® (icosapent ethyl), not only in the overall REDUCE-IT trial population, but also across various subgroups analyzed to date," said St
-- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early Phases of European Launches ---- Positive European Momentum Continues with Progress from Pricing & Reimbursement Efforts and Incremental Revenue Growth Driven Primarily by Spain and the UK ---- Company to Host Virtual Analyst & Investor Day November 14 ---- Company Remains Committed to Maintaining Public Listing – DUBLIN and BRIDGEWATER, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the third quarter ended
-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced two important near-term corporate events: [I] Third Quarter 2024 Financial Results – October 30 – The Company will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, immediately following the close of market trading followed by a conference call with Amarin's senior management team at 5:00 pm ET. Conference Call and Webcast Information: Access to the live call:Go to the investor rela
Aris Mining Corporation (Aris Mining or the Company) (TSX:ARIS) (NYSE-A: ARMN) announces gold production of 99,983 ounces for the first half of 2024 (H1 2024), with 88,613 ounces from Segovia and 11,370 ounces from the Marmato Upper Mine. In the same period in 2023, the Company produced 104,906 ounces of gold, including 94,395 ounces from Segovia and 10,511 ounces from the Marmato Upper Mine. As the Segovia mine plan progresses to higher-grade zones the Company is on track to meet the lower end of its full-year production guidance of 220,000 to 240,000 ounces.Neil Woodyer, CEO of Aris Mining, commented "Our Segovia processing facilities performed well during Q2, consistently achieving over 2
-- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early Phases of European Launches ---- Positive European Momentum Continues with Progress from Pricing & Reimbursement Efforts and Incremental Revenue Growth Driven Primarily by Spain and the UK ---- Company to Host Virtual Analyst & Investor Day November 14 ---- Company Remains Committed to Maintaining Public Listing – DUBLIN and BRIDGEWATER, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the third quarter ended
-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced two important near-term corporate events: [I] Third Quarter 2024 Financial Results – October 30 – The Company will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, immediately following the close of market trading followed by a conference call with Amarin's senior management team at 5:00 pm ET. Conference Call and Webcast Information: Access to the live call:Go to the investor rela
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. Commenting on the Company, Aaron Berg, Amarin's President and CEO, said, "As I begin in my new role as CEO of Amarin, my focus is clear: drive value by focusing on
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)